@phdthesis{Banaszek2013,
  author    = {Banaszek, Agnes},
  title     = {Dual Antigen-Restricted Complementation of a Two-Part Trispecific Antibody for Targeted Immunotherapy of Blood Cancer},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-90174},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2013},
  abstract  = {Cancer cells frequently escape from immune surveillance by down-regulating two important components of the immune defence: antigen-presenting MHC and costimulatory molecules. Therefore several novel anti-tumour compounds that aim to assist the immune system in recognising and fighting cancer are currently under development. Recombinant bispecific antibodies represent one group of such novel therapeutics. They target two different antigens and recruit cytotoxic effector cells to tumour cells. For cancer immunotherapy, bispecific T cell-engaging antibodies are already well characterised. These antibodies target a tumour-associated antigen and CD3ε, the constant molecule of the T cell receptor complex. On the one hand, this study presents the development of a bispecific antibody targeting CD3ε and the rhabdomyosarcoma-associated fetal acetylcholine receptor. On the other hand, it describes a novel two-part trispecific antibody format for the treatment of leukaemia and other haematological malignancies in the context of haematopoietic stem cell transplantation (HSCT). For HSCT, an HLA-identical donor is preferred, but very rarely available. In an HLA-mismatched setting, the HLA disparity could be exploited for targeted cancer treatment. In the present study, a two-part trispecific HLA-A2 × CD45 × CD3 antibody was developed for potential cases in which the patient is HLA-A2-positive, but the donor is not. This holds true for about half the cases in Germany, since HLA-A2 is the most common HLA molecule found here. Combinatorial targeting of HLA-A2 and the leucocyte-common antigen CD45 allows for highly specific dual-antigen restricted tumour targeting. More precisely, two single-chain antibody constructs were developed: i) a single-chain variable fragment (scFv) specific for HLA-A2, and ii) a scFv against CD45, both linked to the VL and the VH domain of a CD3ε-specific antibody, respectively. It turned out that, after the concomitant binding of these constructs to the same HLA-A2- and CD45-expressing cell, the unpaired variable domains of a CD3ε-specific antibody assembled to a functional scFv. In a therapeutic situation, this assembly should exclusively occur on the recipient's blood cancer cells, leading to T cell-mediated cancer cell destruction. In this way, a relapse of disease might be prevented, and standard therapy (radiation and chemotherapy) might be omitted. For both approaches, the antibody constructs were periplasmically expressed in E. coli, purified via His tag, and biochemically characterised. Their binding to the respective targets was proven by flow cytometry. The stimulatory properties of the antibodies were assayed by measuring IL-2 release after incubation with T cells and antigen-expressing target cells. Both the bispecific antibody against rhabdomyosarcoma and the assembled trispecific antibody against blood cancer mediated T-cell activation in a concentration-dependent manner at nanomolar concentrations. For the trispecific antibody, this effect indeed proved to be dual antigen-restricted, as it could be blocked by prior incubation of either HLA-A2- or CD45-specific scFv and did not occur on single-positive (CD45+) or double-negative (HLA-A2- CD45-) target cells. Furthermore, antibodies from both approaches recruited T cells for tumour cell destruction in vitro.},
  subject      = {Immuntherapie},
  language  = {en}
}
@phdthesis{Dagvadorj2016,
  author    = {Dagvadorj, Nergui},
  title     = {Improvement of T-cell response against WT1-overexpressing leukemia by newly developed anti-hDEC205-WT1 antibody fusion proteins},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-149098},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2016},
  abstract  = {Wilms tumor protein 1 (WT1) is a suitable target to develop an immunotherapeutic approach against high risk acute myeloid leukemia (AML), particularly their relapse after allogeneic hematopoietic stem cell transplantation (HSCT). As an intracellular protein traversing between nucleus and cytoplasm, recombinant expression of WT1 is difficult. Therefore, an induction of WT1-specific T-cell responses is mostly based on peptide vaccination as well as dendritic cell (DC) electroporation with mRNA encoding full-length protein to mount WT1-derived peptide variations presented to T cells. Alternatively, the WT1 peptide presentation could be broadened by forcing receptor-mediated endocytosis of DCs. In this study, antibody fusion proteins consisting of an antibody specific to the human DEC205 endocytic receptor and various fragments of WT1 (anti-hDEC205-WT1) were generated for a potential DC-targeted recombinant WT1 vaccine. Anti-hDEC205-WT1 antibody fusion proteins containing full-length or major parts of WT1 were not efficiently expressed and secreted due to their poor solubility and secretory capacity. However, small fragment-containing variants: anti-hDEC205-WT110-35, anti-hDEC205-WT191-138, anti-hDEC205-WT1223-273, and anti-hDEC205-WT1324-371 were obtained in good yields. Since three of these fusion proteins contain the most of the known immunogenic epitopes in their sequences, the anti-hDEC205-WT191-138, anti-hDEC205-WT1223-273, and anti-hDEC205-WT1324-371 were tested for their T-cell stimulatory capacities. Mature monocyte-derived DCs loaded with anti-hDEC205-WT191-138 could induce ex vivo T-cell responses in 12 of 16 blood samples collected from either healthy or HSC transplanted individuals compared to included controls (P < 0.01). Furthermore, these T cells could kill WT1-overexpressing THP-1 leukemia cells in vitro after expansion. In conclusion, alongside proving the difficulty in expression and purification of intracellular WT1 as a vaccine protein, our results from this work introduce an alternative therapeutic vaccine approach to improve an anti-leukemia immune response in the context of allogeneic HSCT and potentially beyond.},
  subject      = {Akute myeloische Leuk{\"a}mie},
  language  = {en}
}
@phdthesis{Gogishvili2006,
  author    = {Gogishvili, Tea},
  title     = {Immunotherapy of allergic disorders in a mouse model of allergic airway inflammation},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-19304},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2006},
  abstract  = {Allergische Erkrankungen sind St{\"o}rungen, bei denen es zu Immunfehlregulationen kommt und die bei empf{\"a}nglichen Individuen zur Entstehung von Allergen spezifischen T-Helfer 2 (TH2) Immunantworten f{\"u}hren. Neuere Untersuchungen deuten darauf hin, dass die f{\"u}r Soforttypallergien charakteristischen TH2 Immunantworten sowohl durch nat{\"u}rlich vorkommende CD4+CD25+ regulatorische T Zellen (Treg) als auch durch Antigen induzierte IL-10-secreting CD4+ regulatorische T Zellen kontrolliert werden k{\"o}nnen. Weiterhin gibt es Hinweise, dass eine erfolgreiche Allergen spezifische Immuntherapie {\"u}ber die Induktion von IL-10 sezernierenden T reg Zellen vermittelt wird. In ersten Teil der Arbeit wird die Effizienz einer Allergen spezifischen Immuntherapie (SIT) in einem Mausmodel f{\"u}r allergische Atemwegsentz{\"u}ndung demonstriert. Als Allergieparameter wurden Allergen spezifisches IgE im Serum, verschiedene TH1 und TH2 Cytokine in der brochoalveol{\"a}ren Lavage Fl{\"u}ssigkeit und nach in vitro Restimulation in Milzzellen untersucht. Weiterhin wurden Histologien von Lungengewebe angefertigt, um das eosinophile Entz{\"u}ndungsinfiltrat und die Asthma typische Becherzellmetaplasie darzustellen. Weiterhin wurden durch FACS Untersuchungen regulatorische T Zellen nachgewiesen. Es konnte gezeigt werden, dass im Mausmodell die intranasale Applikationsform der SIT die allergischen Symptome effizienter bek{\"a}mpfen konnte, als die beim Menschen etablierte subcutane Applikationsform. Um Mechanismen zu definieren die eine SIT effizienter machen k{\"o}nnten wurde ein IL-4/IL13 Inhibitor (QY) als Adjuvans f{\"u}r die SIT benutzt. F{\"u}r den Zytokininhibitor konnte gezeigt werden, dass bei einer Applikation w{\"a}hrend der allergischen Sensibilisierung die Entstehung einer TH2 Immunantwort und die Ausbildung allergischer Symptome verhindert wird. Die Applikation des Inhibitors zusammen mit einer SIT zeigte jedoch keine zus{\"a}tzlichen signifikanten antiallergischen Effekte im Vergleich zur Durchf{\"u}hrung der SIT als Monotherapie. Diese Ergebnisse deuten m{\"o}glicherweise daraufhin , dass der bekannte Wechsel einer TH2 Immunantwort zu einer TH1 Antwort w{\"a}hrend der SIT nicht der Schl{\"u}sselmechanismus zu einer erfolgreichen Behandlung ist. Insbesondere weil unter der SIT auch in unserem Mausmodell die Induktion von IL-10 sezernierenden CD4+ T regulatorischen Zellen mit der Suppression der allergischen Atemwegsentz{\"u}dnung vergesellschaftet waren, so dass m{\"o}glicherwiese diese Zellen f{\"u}r den Therapieerfolg relevant sind . Um die Rolle regulatorischer T Zellen im Allergiemodell n{\"a}her zu beleuchten wurde im 2. Teil der Arbeit ein monoklonaler superagonistischer anti-CD28 Antik{\"o}rper benutzt, von dem bekannt ist dass T regulatorische Zellen in vivo induziert werden. Es konnte gezeigt werden, dass die Applikation des Antik{\"o}rpers w{\"a}hrend der allergischen Sensibilisierung die Etablierung einer TH2 Immunantwort verst{\"a}rkte. Im Gegensatz dazu wurden durch die therapeutische Applikation des anti CD28 Antik{\"o}rpers in einer etablierten Allergie, IL-10 sezernierende CD4+CD25+ T Zellen induziert, welches mit einer Abschw{\"a}chung der gemessenen Allergieparameter einherging.},
  language  = {en}
}
@phdthesis{Hotz2008,
  author    = {Hotz, Christian},
  title     = {Improvement of Salmonella vaccine strains for cancer immune therapy based on secretion or surface display of antigens},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-29548},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2008},
  abstract  = {Cancer immune therapy represents a promising alternative to conventional anti tumour therapy like radiation, surgical excision of the tumour or classical chemotherapy. The biggest advantage of cancer immune therapy is specificity, achieved by targeting tumour-associated antigens with the effector arms of the host immune system. This is believed to result in less adverse effects than standard therapy and reaches presumably also metastatic lesions at distant sites from the primary tumour. However, cancer immune therapy by vaccination against tumour antigens failed to translate into clinical success, yet. Furthermore, despite tremendous clinical efforts malignant disease still results in high mortalities giving rise to the need for novel vaccination-based therapies against cancer. An interesting approach in this respect is the use of bacteria like attenuated salmonellae as carriers for heterologous cancer antigens. In numerous preclinical studies Salmonella-based vaccines could elicit cell mediated immune responses of the CD4+ and CD8+ type against own and heterologous antigens which make them ideally suited for anti tumour therapy. Special delivery systems in Salmonella carriers like surface display or secretion of antigens were shown to be advantageous for the immunological outcome. This work focussed on developing novel Salmonella carriers for immune therapy against cancer. In a first project, TolC, a multifunctional outer membrane protein of E. coli was utilized as membrane anchor for 3 heterologous antigens. Respective TolC fusion proteins encoded on plasmids were analysed for expression, functionality and plasmid stability in different engineered Salmonella strains. The amount of membrane localized recombinant TolC was enhanced in tolC-deficient strains. Furthermore, fusion proteins were functional and plasmid stability was very high in vitro and in vivo. Disappointingly, neither specific CD4+/CD8+ T-cell responses against the model antigen ovalbumin nor CD8+ responses against the cancer antigen BRAFV600E were detectable in murine model systems. However, mice immunized with Salmonella strains displaying an immunodominant epitope of the cancer related prostate specific antigen (PSA) were partially protected from subsequent tumour challenge with a PSA expressing melanoma cell line. Tumour growth in mice immunized with the respective strain was significantly decelerated compared to controls, thus indicating that this surface display system confers protective immunity against tumours. In a second study, the approved typhoid vaccine strain Salmonella enterica serovar Typhi Ty21a (Ty21a) was improved for the hemolysin type I secretion system of E. coli. This secretion system is widely used for heterologous antigen delivery in live bacterial vaccines. It was demonstrated throughout this work that a mutation of rpoS in Ty21a correlated with decreased ability for hemolysin secretion compared to other Salmonella strains. Complementation with rpoS or the presumed downstream target of rpoS, rfaH resulted in enhanced expression and secretion of heterologous hemolysin in Ty21a. Presumably by raising the amount of free antigen, rfaHcomplemented Ty21a elicited higher antibody titres against heterologous hemolysin in immunized mice than controls and even rpoS-positive Ty21a. Therefore, rfaHcomplemented Ty21a could form the basis of a novel generation of vaccines for human use based on (cancer) antigen secretion.},
  subject      = {Impfstoff},
  language  = {en}
}
@phdthesis{Kuehnemundt2024,
  author    = {K{\"u}hnemundt, Johanna},
  title     = {Defined microphysiologic 3D tumour models with aspects from the tumour microenvironment for the evaluation of cellular immunotherapies},
  doi       = {10.25972/OPUS-27667},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-276674},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2024},
  abstract  = {Adoptive cellular immunotherapy with chimeric antigen receptor (CAR) T cells is highly effective in haematological malignancies. This success, however, has not been achieved in solid tumours so far. In contrast to hematologic malignancies, solid tumours include a hostile tumour microenvironment (TME), that poses additional challenges for curative effects and consistent therapeutic outcome. These challenges manifest in physical and immunological barriers that dampen efficacy of the CAR T cells. Preclinical testing of novel cellular immunotherapies is performed mainly in 2D cell culture and animal experiments. While 2D cell culture is an easy technique for efficacy analysis, animal studies reveal information about toxicity in vivo. However, 2D cell culture cannot fully reflect the complexity observed in vivo, because cells are cultured without anchorage to a matrix and only short-term periods are feasible. Animal studies provide a more complex tissue environment, but xenografts often lack human stroma and tumour inoculation occurs mostly ectopically. This emphasises the need for standardisable and scalable tumour models with incorporated TME-aspects, which enable preclinical testing with enhanced predictive value for the clinical outcome of immunotherapies. Therefore, microphysiologic 3D tumour models based on the biological SISmuc (Small Intestinal mucosa and Submucosa) matrix with preserved basement membrane were engaged and improved in this work to serve as a modular and versatile tumour model for efficacy testing of CAR T cells. In order to reflect a variety of cancer entities, TME-aspects, long-term stability and to enhance the read-out options they were further adapted to achieve scalable and standardisable defined microphysiologic 3D tumour models. In this work, novel culture modalities (semi-static, sandwich-culture) were characterised and established that led to an increased and organised tissue generation and long-term stability. Application of the SISmuc matrix was extended to sarcoma and melanoma models and serial bioluminescence intensity (BLI)-based in vivo imaging analysis was established in the microphysiologic 3D tumour models, which represents a time-efficient read-out method for quality evaluation of the models and treatment efficacy analysis, that is independent of the cell phenotype. Isolation of cancer-associated-fibroblasts (CAFs) from lung (tumour) tissue was demonstrated and CAF-implementation further led to stromal-enriched microphysiologic 3D tumour models with in vivo-comparable tissue-like architecture. Presence of CAFs was confirmed by CAF-associated markers (FAP, α-SMA, MMP-2/-9) and cytokines correlated with CAF phenotype, angiogenesis, invasion and immunomodulation. Additionally, an endothelial cell barrier was implemented for static and dynamic culture in a novel bioreactor set-up, which is of particular interest for the analysis of immune cell diapedesis. Studies in microphysiologic 3D Ewing's sarcoma models indicated that sarcoma cells could be sensitised for GD2-targeting CAR T cells. After enhancing the scale of assessment of the microphysiologic 3D tumour models and improving them for CAR T cell testing, the tumour models were used to analyse their sensitivity towards differently designed receptor tyrosine kinase-like orphan receptor 1 (ROR1) CAR T cells and to study the effects of the incorporated TME-aspects on the CAR T cell treatment respectively. ROR1 has been described as a suitable target for several malignancies including triple negative breast cancer (TNBC), as well as lung cancer. Therefore, microphysiologic 3D TNBC and lung cancer models were established. Analysis of ROR1 CAR T cells that differed in costimulation, spacer length and targeting domain, revealed, that the microphysiologic 3D tumour models are highly sensitive and can distinguish optimal from sub-optimal CAR design. Here, higher affinity of the targeting domain induced stronger anti-tumour efficacy and anti-tumour function depended on spacer length, respectively. Long-term treatment for 14 days with ROR1 CAR T cells was demonstrated in dynamic microphysiologic 3D lung tumour models, which did not result in complete tumour cell removal, whereas direct injection of CAR T cells into TNBC and lung tumour models represented an alternative route of application in addition to administration via the medium flow, as it induced strong anti-tumour response. Influence of the incorporated TME-aspects on ROR1 CAR T cell therapy represented by CAF-incorporation and/or TGF-β supplementation was analysed. Presence of TGF-β revealed that the specific TGF-β receptor inhibitor SD-208 improves ROR1 CAR T cell function, because it effectively abrogated immunosuppressive effects of TGF-β in TNBC models. Implementation of CAFs should provide a physical and immunological barrier towards ROR1 CAR T cells, which, however, was not confirmed, as ROR1 CAR T cell function was retained in the presence of CAFs in stromal-enriched microphysiologic 3D lung tumour models. The absence of an effect of CAF enrichment on CAR T cell efficacy suggests a missing component for the development of an immunosuppressive TME, even though immunomodulatory cytokines were detected in co-culture models. Finally, improved gene-edited ROR1 CAR T cells lacking exhaustion-associated genes (PD-1, TGF-β-receptor or both) were challenged by the combination of CAF-enrichment and TGF-β in microphysiologic 3D TNBC models. Results indicated that the absence of PD-1 and TGF-β receptor leads to improved CAR T cells, that induce strong tumour cell lysis, and are protected against the hostile TME. Collectively, the microphysiologic 3D tumour models presented in this work reflect aspects of the hostile TME of solid tumours, engage BLI-based analysis and provide long-term tissue homeostasis. Therefore, they present a defined, scalable, reproducible, standardisable and exportable model for translational research with enhanced predictive value for efficacy testing and candidate selection of cellular immunotherapy, as exemplified by ROR1 CAR T cells.},
  subject      = {Immuntherapie},
  language  = {en}
}
@phdthesis{Landwehr2023,
  author    = {Landwehr, Laura-Sophie},
  title     = {Steroid Hormones and Cancer Immunity - learning from Adrenocortical Carcinoma},
  doi       = {10.25972/OPUS-25189},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-251895},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2023},
  abstract  = {Adrenocortical carcinoma (ACC) is a rare, but highly aggressive endocrine malignancy. Tumor-related hypercortisolism is present in 60 \% of patients and associated with worse outcome. While cancer immunotherapies have revolutionized the treatment of many cancer entities, the results of initial studies of different immune checkpoint inhibitors in ACC were heterogeneous. Up to now, five small clinical trials with a total of 121 patients have been published and demonstrated an objective response in only 17 patients. However, one of the studies, by Raj et al., reported a clinically meaningful disease control rate of 52 \% and a median overall survival of almost 25 months suggesting that a subgroup of ACC patients may benefit from immunotherapeutic approaches. Following the hypothesis that some ACCs are characterized by a glucocorticoid-induced T lymphocytes depletion, several studies were performed as part of the presented thesis. First, the immune cell infiltration in a large cohort of 146 ACC specimens was investigated. It was demonstrated for the first time, and against the common assumption, that ACCs were infiltrated not only by FoxP3+ regulatory T cells (49.3 \%), but also that a vast majority of tumor samples was infiltrated by CD4+ TH cells (74 \%) and CD8+ cytotoxic T cells (84.3 \%), albeit the immune cell number varied heterogeneously and was rather low (median: 7.7 CD3+ T cells / high power field, range: 0.1-376). Moreover, the presence of CD3+-, CD4+- and CD8+ ACC-infiltrating lymphocytes was associated with an improved recurrence-free (HR: 0.31 95 \% CI 0.11-0.82) and overall survival (HR: 0.47 96 \% CI 0.25-0.87). Particularly, patients with tumor-infiltrating CD4+ TH cells without glucocorticoid excess had a significantly longer overall survival compared to patients with T cell-depleted ACC and hypercortisolism (121 vs. 27 months, p = 0.004). Hence, the impact of glucocorticoids might to some extent be responsible for the modest immunogenicity in ACC as hypercortisolism was reversely correlated with the number of CD4+ TH cells. Accordingly, CD3+ T cells co-cultured with steroidogenic NCI-H295R ACC cells demonstrated in vitro an enhanced anti-tumoral cytotoxicity by secreting 747.96 ±225.53 pg/ml IFN-γ in a therapeutically hormone-depleted microenvironment (by incubation with metyrapone), versus only 276.02 ±117.46 pg/ml IFN-γ in a standard environment with glucocorticoid excess. Other potential biomarkers to predict response to immunotherapies are the immunomodulatory checkpoint molecules, programmed cell death 1 (PD-1) and its ligand PD-L1, since both are targets of antibodies used therapeutically in different cancer entities. In a subcohort of 129 ACCs, expressions of both molecules were heterogeneous (PD-1 17.4 \%, range 1-15; PD-L1 24.4 \%, range 1 - 90) and rather low. Interestingly, PD-1 expression significantly influenced ACC patients´ overall (HR: 0.21 95 \% CI 0.53-0.84) and progression- free survival (HR: 0.30 95 \% CI 0.13-0.72) independently of established factors, like ENSAT tumor stage, resection status, Ki67 proliferation index and glucocorticoid excess, while PD-L1 had no impact. In conclusion, this study provides several potential explanations for the heterogeneous results of the immune checkpoint therapy in advanced ACC. In addition, the establishment of PD-1 as prognostic marker can be easily applied in routine clinical care, because it is nowadays anyway part of a detailed histo-pathological work-up. Furthermore, these results provide the rationale and will pave the way towards a combination therapy using immune checkpoint inhibitors as well as glucocorticoid blockers. This will increase the likelihood of re-activating the immunological anti-tumor potential in ACC. However, this will have to be demonstrated by additional preclinical in vivo experiments and finally in clinical trials with patients.},
  subject      = {Steroidhormon},
  language  = {en}
}
@phdthesis{Letschert2019,
  author    = {Letschert, Sebastian},
  title     = {Quantitative Analysis of Membrane Components using Super-Resolution Microscopy},
  doi       = {10.25972/OPUS-16213},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-162139},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2019},
  abstract  = {The plasma membrane is one of the most thoroughly studied and at the same time most complex, diverse, and least understood cellular structures. Its function is determined by the molecular composition as well as the spatial arrangement of its components. Even after decades of extensive membrane research and the proposal of dozens of models and theories, the structural organization of plasma membranes remains largely unknown. Modern imaging tools such as super-resolution fluorescence microscopy are one of the most efficient techniques in life sciences and are widely used to study the spatial arrangement and quantitative behavior of biomolecules in fixed and living cells. In this work, direct stochastic optical reconstruction microscopy (dSTORM) was used to investigate the structural distribution of mem-brane components with virtually molecular resolution. Key issues are different preparation and staining strategies for membrane imaging as well as localization-based quantitative analyses of membrane molecules. An essential precondition for the spatial and quantitative analysis of membrane components is the prevention of photoswitching artifacts in reconstructed localization microscopy images. Therefore, the impact of irradiation intensity, label density and photoswitching behavior on the distribution of plasma membrane and mitochondrial membrane proteins in dSTORM images was investigated. It is demonstrated that the combination of densely labeled plasma membranes and inappropriate photoswitching rates induces artificial membrane clusters. Moreover, inhomogeneous localization distributions induced by projections of three-dimensional membrane structures such as microvilli and vesicles are prone to generate artifacts in images of biological membranes. Alternative imaging techniques and ways to prevent artifacts in single-molecule localization microscopy are presented and extensively discussed. Another central topic addresses the spatial organization of glycosylated components covering the cell membrane. It is shown that a bioorthogonal chemical reporter system consisting of modified monosaccharide precursors and organic fluorophores can be used for specific labeling of membrane-associated glycoproteins and -lipids. The distribution of glycans was visualized by dSTORM showing a homogeneous molecule distribution on different mammalian cell lines without the presence of clusters. An absolute number of around five million glycans per cell was estimated and the results show that the combination of metabolic labeling, click chemistry, and single-molecule localization microscopy can be efficiently used to study cell surface glycoconjugates. In a third project, dSTORM was performed to investigate low-expressing receptors on cancer cells which can act as targets in personalized immunotherapy. Primary multiple myeloma cells derived from the bone marrow of several patients were analyzed for CD19 expression as potential target for chimeric antigen receptor (CAR)-modified T cells. Depending on the patient, 60-1,600 CD19 molecules per cell were quantified and functional in vitro tests demonstrate that the threshold for CD19 CAR T recognition is below 100 CD19 molecules per target cell. Results are compared with flow cytometry data, and the important roles of efficient labeling and appropriate control experiments are discussed.},
  subject      = {Fluoreszenzmikroskopie},
  language  = {en}
}
@phdthesis{Mestermann2020,
  author    = {Mestermann, Katrin},
  title     = {Pharmacological control of CAR T-cells by dasatinib},
  doi       = {10.25972/OPUS-18056},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-180562},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2020},
  abstract  = {Cellular therapies using chimeric antigen receptor (CAR) modified T cells to eradicate tumor cells have been a major breakthrough in the treatment of hematologic malignancies. However, there are no measures to control CAR T cell activity after infusion, which is mostly required in cases of CAR T cell overreaction, e.g. cytokine release syndrome, or in the case of T cell failure, e.g. caused by exhaustion. In our study, we identified the tyrosine kinase inhibitor (TKI) dasatinib (© Sprycel) as a suitable agent to steer CAR T cells in vitro and in vivo. We show that single treatment of CD4+ and CD8+ CAR T cells with dasatinib conferred either partial or complete inhibition, depending on the applied concentration. The blockade was immediate and encompassed spe-cific lysis, cytokine secretion and proliferation following antigen encounter. The mechanism relied on reduced phosphorylation of key kinases in the CAR signaling cascade, which led to abrogation of nuclear factor of activated T-cells (NFAT) signaling. Importantly, inhibition was fully reversible by dasatinib withdrawal. In vivo, dasatinib blocked CAR T cell function without impairing the engraftment of CAR T cells or their subsequent anti tumor function once dasatinib administration was discontinued. We therefore introduce dasatinib as a new tool to efficiently block CAR T cells in vitro and in vivo, with data suggesting that dasatinib can be used in a clinical setting to mitigate toxicity after adaptive transfer of CAR modified T cells and other forms of T cell based immunotherapy. Additionally we show that intermittent inhibition of CAR T cells by dasatinib im-proves the efficacy of CAR T cell therapy. By pausing T cells for short periods of time in vi-vo, upregulation of programmed death protein 1 (PD-1) and subsequent induction of exhaus-tion was prevented, which increased the expansion of T cells and the rate of tumor eradica-tion. Our data therefore suggest that dasatinib can additionally be used to overcome T cell exhaustion that is induced by massive tumor burden and upregulation of inhibitory receptors.},
  subject      = {Immuntherapie},
  language  = {en}
}
@phdthesis{Monjezi2018,
  author    = {Monjezi, Razieh},
  title     = {Engineering of chimeric antigen receptor T cells with enhanced therapeutic index in cancer immunotherapy using non-viral gene transfer and genome editing},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-152521},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2018},
  abstract  = {The advances in genetic engineering have enabled us to confer T cells new desired functions or delete their specific undesired endogenous properties for improving their antitumor function. Due to their efficient gene delivery, viral vectors have been successfully used in T-cell engineering to provide gene transfer medicinal products for the treatment of human disease. One example is adoptive cell therapy with T cells that were genetically modified with gamma-retroviral and lentiviral (LV) delivery vectors to express a CD19-specific chimeric antigen receptor (CAR) for cancer treatment. This therapeutic approach has shown remarkable results against B-cell malignancies in pilot clinical trials. Consequently, there is a strong desire to make CAR T cell therapy scalable and globally available to patients. However, there are persistent concerns and limitations with the use of viral vectors for CAR T cell generation with regard to safety, cost and scale of vector production. In order to address these concerns, we aimed to improve non-viral gene transfer and genome editing tools as an effective, safe and broadly applicable alternative to viral delivery methods for T-cell engineering. In the first part of the study, we engineered CAR T cells through non-viral Sleeping Beauty (SB) transposition of CAR genes from minimalistic DNA vectors called minicircles rather than conventional SB plasmids. This novel approach dramatically increased stable gene transfer rate and cell viability and resulted in higher yield of CAR+ T cells without the need of long ex vivo expansion to generate therapeutic doses of CAR+ T cells. Importantly, CD19-CAR T cells modified by MC-based SB transposition were equally effective as LV transduced CD19-CAR T cells in vitro and in a murine xenograft model (NSG/Raji-ffLuc), where a single administration of CD8+ and CD4+ CAR T cells led to complete eradication of lymphoma and memory formation of CAR T cells after lymphoma clearance. To characterize the biosafety profile of the CAR T cell products, we did the most comprehensive genomic insertion site analysis performed so far in T cells modified with SB. The data showed a close-to-random integration profile of the SB transposon with a higher number of insertions in genomic safe harbors compared to LV integrants. We developed a droplet digital PCR assay that enables rapid determination of CAR copy numbers for clinical applications. In the second part of the study, we ablated expression of PD-1, a checkpoint and negative regulator of T cell function to improve the therapeutic index of CAR T cells. This was accomplished using non-viral CRISPR/Cas9 via pre-assemble Cas9 protein and in vitro-transcribed sgRNA (Cas9 RNP). Finally, we combined our developed Cas9 RNP tool with CAR transposition from MC vectors into a single-step protocol and successfully generated PD-1 knockout CAR+ T cells. Based on the promising results achieved from antibody-mediated PD-1 blockade in the treatment of hematological and solid tumors, we are confident that PD-1 knockout CAR T cells enhance the potency of CAR T cell therapies for treatment of cancers without the side effects of antibody-based therapies. In conclusion, we provide a novel platform for virus-free genetic engineering of CAR T cells that can be broadly applied in T-cell cancer therapy. The high level of gene transfer rate and efficient genome editing, superior safety profile as well as ease-of-handling and production of non-viral MC vectors and Cas9 RNP position our developed non-viral strategies to become preferred approaches in advanced cellular and gene-therapy.},
  subject      = {Krebs <Medizin>},
  language  = {en}
}
@phdthesis{Stuehler2010,
  author    = {St{\"u}hler, Claudia},
  title     = {Strategies to prevent graft-versus-host disease and augment anti-fungal immunity in allogeneic hematopoietic stem cell transplant recipients},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-51957},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2010},
  abstract  = {Allogeneic hematopoietic stem cell transplantation (HSCT) is often the only effective treatment for patients with hematological malignancies, but its curative potential is often limited by the development of acute or chronic graft-versus-host disease (GvHD). Although extensive immunosuppressive therapy is highly efficient in the prevention or treatment of GvHD, it greatly increases the risk for life-threatening opportunistic fungal or viral infections and the recurrence of malignant disease. The possibility to selectively deplete alloreactive T cells from donor grafts prior or after transplantation would greatly diminish the need for immunosuppressive therapy in the transplant recipient and thereby greatly improve its clinical outcome. The molecular chaperone heat shock protein of 90 kDa (Hsp90) has been previously shown to stabilize many signal transduction proteins involved in T lymphocyte activation and proliferation and is furthermore able to exert anti-apoptotic effects in different cell types. The aim of this study was therefore to investigate the possibility to selectively target activated, proliferating T cells in lymphocyte populations by inhibition of Hsp90, without compromising viability and function of non-reactive T cell populations including pathogen-specific T lymphocytes. It could be shown in this work, that activated T cells are indeed more prone to apoptotic cell death in the presence of Hsp90 inhibitors than resting cells and that treatment of mixed lymphocyte cultures with such inhibitors eliminates the proliferation of alloreactive cells. In contrast, T cells remaining in a resting state during inhibitor treatment remain viable and also display functional virus-specific responses after inhibitor removal. These data suggest, that Hsp90 could represent a novel target for selective depletion of alloreactive T cells and that application of Hsp90 inhibitors could be a potential approach to prevent or treat GvHD without impairing pathogen-specific T cell immunity. In the second part of this work, the immune responses to strictly defined antigens of the opportunistic pathogenic fungus Aspergillus fumigatus were characterized. Opportunistic fungal infections are highly prevalent in immunocompromized and immunosuppressed individuals, especially in HSCT recipients suffering from GvDH. Although antifungal treatment is permanently improved, invasive fungal infections are still often fatal. In healthy individuals clinical disease is rare, because innate and adaptive immunity act in conjunction to protect the host. Therefore one possible strategy to prevent and treat life-threatening fungal infections in immunocompromized patients is to improve host resistance by augmenting the antifungal functions of the immune system, for example by vaccination or adoptive transfer of antigen-specific T cells. Based on previous findings, the objective of this dissertation was to identify and characterize distinct immunogenic A. fumigatus antigens that could be used for clinical application like vaccination or ex vivo generation of antigen-specific T cells and to characterize the interaction of this antigen-specific lymphocytes with cells of the innate immune system. First, memory T cell responses to different recombinant A. fumigatus proteins in healthy individuals were evaluated. The majority of tested donors displayed stable CD4+ TH1 responses to the Crf1 protein, whereas responses to the other antigens tested could only be detected in a limited number of donors, qualifying Crf1 as potential candidate antigen for clinical use. It was also possible to identify an immunodominant MHC class II DRB1*04-restricted epitope of Crf1 and to generate T cell clones specific for this epitope. This Crf1-specific T cell clones could be specifically activated by dendritic cells fed with synthetic peptide, recombinant protein or germinating A. fumigatus conidia or outgrown hyphae. Interestingly, these A. fumigatus-specific T cell clones also responded to stimulation with Candida albicans, which likewise causes opportunistic infections in immunocompromized patients and encodes for a glucosyltransferase similar to A. fumigatus Crf1. It was also possible to show that supernatant harvested from activated Crf1-specific T cell cultures was able to significantly increase fungal killing by monocytes. These data indicate that the specified FHT epitope of the A. fumigatus protein Crf1 could be potentially used as antigen for vaccination protocols or for the generation of Aspergillus-specific effector T cells for adoptive transfer.},
  subject      = {Transplantat-Wirt-Reaktion},
  language  = {en}
}